Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access               Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain XLRN message board posts where the ticker symbol XLRN has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest XLRN SEC Filings

Filings Format Description Filing Date File/Film Number
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-18-007615 (33 Act)  Size: 13 KB
2018-09-04 333-190417
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-011049 Size: 8 KB
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001280600-18-000057 (34 Act)  Size: 5 MB
2018-08-02 001-36065
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001280600-18-000055 (34 Act)  Size: 159 KB
2018-08-02 001-36065
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001280600-18-000050 (34 Act)  Size: 68 KB
2018-07-26 001-36065
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001280600-18-000046 (34 Act)  Size: 79 KB
2018-07-09 001-36065
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-009494 Size: 6 KB
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001179110-18-009490 Size: 6 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-009302 Size: 9 KB
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001280600-18-000044 (34 Act)  Size: 79 KB
2018-06-28 001-36065
More XLRN SEC Filings

Related news from
Thu, 20 Sep 2018
12:00:00 +0000
Today's Research Reports on Trending Tickers: Acceleron Pharma and Tesaro
NEW YORK, NY / ACCESSWIRE / September 20, 2018 / Wall Street posted mixed results on Wednesday as tech shares weakened and trade tensions continued to rise. The Dow Jones Industrial Average gained 0.61 ...
Tue, 18 Sep 2018
18:44:22 +0000
Analyst: Acceleron's Blood Disorder Candidate Luspatercept Has Blockbuster Potential
Acceleron Pharma Inc (NASDAQ: XLRN ) has a rich pipeline that positions the stock for additional upside, according to Piper Jaffray. The Analyst Analyst Danielle Brill upgraded Acceleron from Neutral to ...
Tue, 04 Sep 2018
19:17:00 +0000
Here's Why Acceleron Pharma Rose 24% in August
Mr. Market thinks the double-digit slide from July was overdone. He may be right.
Tue, 14 Aug 2018
23:34:55 +0000
Edited Transcript of XLRN earnings conference call or presentation 2-Aug-18 9:00pm GMT
Q2 2018 Acceleron Pharma Inc Earnings Call
Wed, 08 Aug 2018
20:17:51 +0000
Could Biotech Giant Celgene Join Tesla In The Private Markets?
Biotech giant Celgene could go private at 120 per share, an analyst suggested Wednesday after similarly sized electric-car maker Tesla confirmed it's discussing the possibility.
Sat, 04 Aug 2018
17:11:00 +0000
Here's Why Acceleron Pharma Inc. Lost 10.2% in July
The pharma company saw its share price adjusted after a huge gain at the end of June.
Fri, 03 Aug 2018
11:52:00 +0000
The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 2) Akcea Therapeutics Inc (NASDAQ: AKCA ) Arbutus Biopharma Corp ...
Thu, 02 Aug 2018
22:25:10 +0000
Acceleron Pharma (XLRN) Reports Q2 Loss, Tops Revenue Estimates
Acceleron (XLRN) delivered earnings and revenue surprises of 1.56% and 7.94%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Thu, 02 Aug 2018
21:21:39 +0000
Acceleron: 2Q Earnings Snapshot
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 63 cents. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
Thu, 02 Aug 2018
20:05:00 +0000
Acceleron Reports Second Quarter 2018 Operating and Financial Results
– MEDALIST and BELIEVE Phase 3 trials met all primary and key secondary endpoints –
Thu, 02 Aug 2018
11:53:36 +0000
Acceleron Pharma Q2 Earnings Preview
Acceleron Pharma (NASDAQ: XLRN ) releases its next round of earnings Thursday. Here's Benzinga's essential guide to Acceleron Pharma's Q2 earnings report. Earnings and Revenue Based on management's projections, ...
Thu, 26 Jul 2018
11:00:00 +0000
Acceleron to Webcast Second Quarter 2018 Operating and Financial Results on August 2, 2018
Acceleron Pharma Inc. (XLRN) today announced it will host a webcast and conference call on Thursday, August 2, 2018 at 5:00 p.m. EDT to discuss its second quarter 2018 operating and financial results. The webcast will be accessible under "Events & Presentations" in the Investors/Media page of the company's website at The archived webcast will be available for replay on the Acceleron website approximately two hours after the event.
Fri, 20 Jul 2018
11:34:13 +0000
What Analysts Recommend for Celgene ahead of Its Q2 2018 Results
On July 9, Celgene (CELG) and Acceleron Pharma announced their results from the Phase 3 BELIEVE trial. Celgene and Acceleron conducted the Phase 3 BELIEVE trial to evaluate the safety and efficacy of luspatercept and the best supportive care compared to a placebo and the best supportive care for the treatment of adult individuals with transfusion-dependent beta thalassemia.
Wed, 18 Jul 2018
11:15:00 +0000
Free Pre-Market Technical Recap on Genesis Healthcare and Three Additional Healthcare Stocks
On Tuesday, July 17, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, assessed the following Healthcare equities this morning: Brookdale Senior Living Inc. (NYSE: BKD), Envision Healthcare Corp. (NYSE: EVHC), Genesis Healthcare Inc. (NYSE: GEN), and Acceleron Pharma Inc. (NASDAQ: XLRN).
Fri, 13 Jul 2018
16:45:53 +0000
Morgan Stanley Downgrades Acceleron As Valuation Reaches Price Target
Acceleron Pharma Inc (NASDAQ: XLRN) shares have gained about 39 percent since June 28 in reaction to positive Phase 3 study results for its luspatercept in low-to intermediate-risk myelodysplastic syndromes. The rally sent Morgan Stanley analyst Matthew Harrison to the sidelines. Acceleron's luspatercept data is strong, positioning the company for a filing in the first half of 2019, but there is possibility of limited near-term upside, Harrison said in a Friday morning note.
Thu, 12 Jul 2018
11:00:00 +0000
Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation for ACE-083, the Company’s locally acting “Myostatin+” muscle agent, for the treatment of patients with facioscapulohumeral muscular dystrophy (FSHD). “We are pleased to receive orphan drug designation for ACE-083, which has shown the potential to address an area of high unmet medical need,” said Robert K. Zeldin, M.D., Chief Medical Officer of Acceleron.
Wed, 11 Jul 2018
13:41:01 +0000
Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More
Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.
Tue, 10 Jul 2018
18:50:06 +0000
Celgene, Acceleron Report Positive Data on Thalassemia Drug
Celgene (CELG) and partner Acceleron Pharma report positive results on luspatercept from a late-stage study. This is the second positive phase III study for the candidate.
Tue, 10 Jul 2018
15:52:00 +0000
Upbeat Celgene Data Not Enough to Lift Biotech Sector
Shares of Celgene (CELG) and Acceleron Pharma (XLRN) are climbing on Tuesday, after announcing that Luspatercept, the anemia drug the biotech firms are jointly developing, performed well in a Phase III study. Acceleron is up 2.3% to $48.50, while Celgene is climbing 0.9% to $84.60.
Tue, 10 Jul 2018
12:11:27 +0000
Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 9) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Arrowhead Pharmaceuticals ...

"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "The collective wisdom of the members and distributed in an unselfish manner is what I find to be the most valuable asset of the group." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards